COVID-19 Funding Opportunities & FAQs

The availability of COVID-19 grants and funding opportunities to support research is rapidly evolving. Many investigators also have questions about how to deal with grant program interruptions. Listed below are links to information/FAQs from several major federal agencies on how to deal with grant interruptions. Following that is a collection of COVID-19 funding opportunities to support research from a variety of federal agencies, foundations, and organizations. Check back often for updated lists.

Please contact Lori Uttech-Hanson to share relevant funding sources at

Dealing with Grant Interruptions, Delays or Flexibilities due to COVID

Many UW-Madison researchers and research administrative staff have questions about how to deal with grant interruptions, delays, or flexibilities due to the pandemic and temporary closure of facilities. The NIH has a very informative webpage dedicated to FAQs, which tend to direct you to your Program Officer in most cases (see link below). All federal agencies understand what is going on, but may have less thorough information than NIH. If you find your question is not addressed on the agency’s website, it is advisable to email the Program Officer, copying your RSP accountant.  RSP also has different sponsors’ COVID-19 information posted on their website. Please click on the links below for guidance and FAQs related to grant delays and interruptions from several major funders and additional information posted on the RSP website:

Funding Opportunities Related to COVID-19

This is an accordion element with a series of buttons that open and close related content panels.

Grant Database Lists (Free Access to Collections of Funding Announcements)

Ex Libris Research Professional:  The Ex Libris Research Professional together with Pivot® funding services are providing free access to a list of select funding opportunities related to combatting the coronavirus and COVID-19. By raising awareness of these resources, which are offered from a wide range of global funders, they hope to help researchers expand their scholarly efforts to understand and contend with this global pandemic.
Link is:

Grant Forward: GrantForward has provided a free list of grants related to addressing COVID-19 ranging from small foundation to large-scale federal research grants in an effort to help researchers and others find science-based solutions to address this global pandemic.
Link is:

GrantStation: GrantStation’s list includes funding opportunities for nonprofits, small businesses, journalists, and artists.
Link is:

InfoEd Global:  InfoEd Global shares this library of COVID-19 funding opportunities and resources for researchers and the broader community at large. This site is updated daily.
Link is:  

National Institutes of Health: Funding specific to COVID-19 (also in table below with more information).
Link is: 

Pivot: Pivot has given free access to a list of COVID-19 related funding sources, and they are updating the list weekly.
Link is:

WI Center for Technology Commercialization: The CTC has posted a list of federal agencies that are supporting research and development in response to the coronavirus.  Many of these agencies are included in the panels below on this medRAMP website, with information on specific funding announcements.
Link is:

Stermlyne Research Software: Streamlyne’s intelligent natural language processing tool enables researchers to locate articles on SARS-CoV-2  and related viruses quickly and efficiently within the COVID-19 Open Research Dataset (CORD-19) created by the Allen Institute for AI, in partnership with several tech companies and the OSTP.  The dataset is linked to the World Health Organization (WHO) database of publications on coronavirus disease and other resources.  The website also provides a sample list of some of the most promising COVID-19 research efforts at universities and independent research institutions.
Link is:

InnoCentive COVID-19 Challenges: This page is exclusively for Coronavirus related challenges. InnoCentive and Wazoku are initiating the first of these challenges and are already working with organizations to design and post others. Each challenge will have a specific problem area defined for either required Solutions or Ideas to be submitted. Clients from the public and private sectors will be named in the challenges as having provided support, funding and reviewing expertise for solutions submitted.
• Link is:

National Institutes of Health

In addition to the table below, NIH COVID-19 related announcements are posted here, with COVID-19 resources found at this link. 

National Institutes of Health

wdt_ID Sponsor Program Funding Deadline Notice Activity Code
1 NIA, NIAID, NIDDK, NIDA, NIMH, NIEHS, NICHD, NIAAA, NIBIB, NHGRI, NIMHD, NCATS, NIDCH, NCI, NIDCR Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) Must reflect your needs Varies by awarding IC PA-18-935
17 NIAID, NIA Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) Not limited 5/13/2020; 9/13/2020; 1/13/2021; 5/13/2021; 9/13/2021; 1/13/2022; 5/13/2022; 9/13/2022; 1/13/2023 PAR-20-139 R01
19 NCATS Notice of Special Interest regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus Limited to amount of current parent 5/15/2020 - Applications accepted until 1/25/2022 NOT-TR-20-017 Admin Supp
20 NCATS Notice of Special Interest regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus Limited to no more than 25% total costs of the amount of the current parent award 5/15/2020 - Applications accepted through 1/25/2022 NOT-TR-20-016 Admin Supp
29 NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB, NCATS, Common Fund, NCATS, NIAAA Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional) Not limited See Emergency Notice of Special Interest by IC; Expires 9/08/2025 PA-20-135 333
32 NIMHD, NIA, NIDA, NCI Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) Not limited 10/5/2020 and subsequent standard R01 deadlines with expiration date of 9/08/2023 PA-20-172 R01
36 NIBIB Point-of-Care Technology Research Network (POCTRN) Fast-Track Program for COVID-19 Test Development and Distribution Phase 0: $25,000; Phase 1: Expected to range from $500,000 to millions; Unlimited; Phase 2: Tens of millions Rolling (selection process began 4/29/2020 to continue until further notice)
52 NIBIB Rapid Acceleration of Diagnostics (RADx) Up to $500,000 million Rolling submission until further notice See:
72 FIC, NIAID Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) $230,000/year new; $276,000/year renewal 8/14/2020; 8/03/2021 & 8/03/2022 PAR-20-229 D43
73 NIMH Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19) Data N/A NOT-MH-20-061
Sponsor Program Funding Deadline Notice Activity Code

Agency for Healthcare Research and Quality

  • Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic (NOT-HS-21-010): The purpose of this Special Emphasis Notice (SEN) is to inform the research community that the Agency for Healthcare Research and Quality is interested in receiving health services research grant applications to advance our nation’s understanding of the substance use disorder crisis and provide solutions for addressing it. In this SEN, AHRQ is interested in health services research to prevent, identify and treat substance use disorders with a high degree of interest in applications that respond to the following three specific areas of focus: (1) Dissemination and implementation of evidence-based, non-pharmacological and behavioral interventions that can treat multiple substances or polysubstance use in ambulatory care and primary care settings, with a particular interest in substances for which pharmacological treatments are not available. (2) Development and testing of healthcare services interventions in primary care and ambulatory care settings to address substance use disorder that consider the social, environmental, economic and psychological factors that contribute to substance use disorder. Examples include care coordination, integration of substance use services in ambulatory care settings, or integration of population health approaches with primary care. Applications that take advantage of the natural experiment caused by the COVID-19 pandemic to examine how changes in service delivery (such as expanded use of telehealth) affect access to care, quality of care, and health inequities are particularly welcome. (3) Understanding and addressing the effect of substance use disorder on whole person health and the development and/or management of other chronic conditions. The Agency encourages research teams to submit applications in response to this emphasis using AHRQ’s standing R18, R03, and R01 funding mechanisms (PA-18-793PA-18-794PA-18-795). AHRQ also is interested in receiving career development awards (PA-20-067 and PA-17-232) that propose developing generalizable health service research skills through projects related to the substance use disorder crisis. Additionally, AHRQ has interest in receiving dissertation award grant proposals that relate to the substance use disorder crisis (PA-18-765). Applicants should consider this SEN active until March 15, 2023.
  • General Funding Announcements:  AHRQ does not currently have any COVID-19-focused funding opportunities. Investigators interested in seeking funding for COVID-19-related research consistent with AHRQ’s priorities can use our general funding announcements. In addition, AHRQ grantees are encouraged to contact their project officers with novel ideas for implementation and future research.

Department of Defense

Department of Defense

wdt_ID Sponser Program Funding Deadline
1 DoD Request for Information for PPE in response to COVID-19 N/A 3/24/2020 (information accepted on a rolling basis)
12 DoD Dept. of the Army - USAMRAA Department of Defense HIV/AIDS Prevention Program - W81XWH-21-DHAPP See NOFO 9/23/2022
13 DoD Defense Threat Reduction Agency Strategic Trends Division Broad Agency Announcement (BAA) HDTRA1-20-S-0002BAA $350,000 (Offers may submit a White Paper package to any of the BAA’s Thrust Areas of research at any time. If an Offer’s Phase I package is approved, the Offer will be invited to submit a Phase II package (Proposal). 3/02/2025

Patient-Centered Outcomes Research Institute

Broad PCORI Funding Announcements: Addressing Disparities; Assessment of Prevention, Diagnosis and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems. 

PCORI continues to support COVID-19 related research in their Cycle 3 2021 Broad PCORI Funding Program. Designating COVID-19 as a Special Emphasis Area, priority topics are management and survivorship of post-acute COVID-19; impact of COVID-19 on disproportionately affected populations; and impact of COVID-19-related social isolation and loneliness on health outcomes.

Due Dates: CYCLE 3: Required LOIs due October 5, 2021; invited full applications due January 11, 2022

Check this website:

Centers for Disease Control and Prevention

  • RFA-CK-22-003: Emerging Infections Sentinel Networks (EISN) Research Department of Health and Human Services Centers for Disease Control and Prevention – ERA: The purpose of this Notice of Funding Opportunity (NOFO) is to provide a funding mechanism for Emerging Infections Sentinel Networks (EISN) research activities, specifically within a network of emergency departments (EDs). The EISN program will assist in operating emergency department provider-based sentinel networks. These networks will contribute to surveillance for emerging infectious diseases (EID), such as those caused by agents of bioterrorism, pathogens of pandemic potential, drug-resistant, foodborne or waterborne microorganisms, and vaccine-preventable or potentially vaccine-preventable diseases (e.g., Bacillus anthracis. new coronaviruses, Clostridium difficile, carbapenem-resistant Enterobacteriaceae, viral hepatitis and respiratory viruses of epidemic or pandemic potential, tuberculosis, sexually transmitted diseases), and help inform operational public health and healthcare decisions during public health emergencies (e.g., assessment of rapid screening and triage protocols during surge of infectious disease cases presenting for clinical care; assessment of clinical characteristics and development of rapid epidemiologic studies during emergencies to improve the understanding of the clinical characteristics, impacts and outcomes of new and emerging diseases), help better understand and address the disproportionate impact of EIDs on underserved and disadvantaged populations, and enhance information exchange.
    Due Date: 11/01/2021
    Funding Amount: $300,000
  • CDC-RFA-PS22-2203: Comprehensive High-Impact HIV Prevention Programs for Young Men of Color Who Have Sex with Men and Young Transgender Persons of Color:  The CDC announces the availability of fiscal year 2022 funds for a cooperative agreement program for community-based organizations (CBOs) to develop and implement high-impact human immunodeficiency virus (HIV) prevention programs in the following two categories: Category A: HIV prevention services for Young Men of Color Who Have Sex with Men (YMSM of color) and their partners regardless of age, gender, and race/ethnicity Category B: HIV prevention services for Young Transgender Persons of Color (YTG persons of color) and their partners regardless of age, gender, and race/ethnicity NOTE: Throughout this funding opportunity announcement, “young” and “youth” are defined as individuals between the ages of 13-34 years.   CBOs are uniquely positioned to complement and extend the reach of HIV prevention efforts implemented by state and local health departments through the optimization of services across public, private, and other CBOs to achieve objectives of increased HIV diagnoses identification, referral for pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP) services, earlier entry to HIV care, and increased consistency of care. The program purpose is to implement comprehensive high-impact HIV prevention programs to address health disparities among YMSM of color, YTG persons of color, and their partners with the goal of reducing HIV transmission and HIV-associated morbidity and mortality. This program aligns with the goals of the HIV National Strategic Plan, 2021-2025 (HIV Plan)1 and the Division of HIV Prevention (DHP) Strategic Plan 2017-20202, supporting the ambitious goals of reducing all new HIV infections by 75% by 2025 and 90% by 2030. This program also complements the Department of Health and Human Services (HHS) initiative of Ending the HIV Epidemic in the United States (EHE)3 and supports the HIV Plan health equity-related goals of addressing social determinants of health (SDH) and syndemics affecting HIV-related outcomes.
    Due Date: 11/19/2021
    Funding Amount: See NOFO
  • Forecasted – RFA-IP-22-004: US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings: Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.
    Due Date: Anticipated 2/01/2022
    Funding Amount: $11,600,000
    Website (search RFA#):
  • Forecasted – CDC-RFA-CK22-2203: Strengthening Healthcare Infection Prevention and Control and Improving Patient Safety in the United States: The COVID-19 pandemic highlighted gaps in infection prevention and control (IPC) knowledge and practice in U.S. healthcare settings. IPC in healthcare stops the spread of infections, preventing illness and death and protecting patients and healthcare personnel. There is a need to strengthen healthcare IPC practices, inform IPC recommendations, improve how healthcare personnel IPC competencies are assessed, and develop evidence-based approaches to IPC training and education. This Notice of Funding Opportunity (NOFO) provides real-world implementation solutions for CDC’s evidence-based guidance, during both normal operations and during emergencies.   Through this NOFO, CDC will continue to protect Americans by improving the safety and quality of healthcare.  This NOFO supports the priorities of the National Center for Emerging and Zoonotic Infectious Diseases, including the prevention of the spread of infectious diseases by enhancing healthcare infection prevention and control (IPC). This NOFO will engage organizations (e.g., academic institutions, healthcare systems, and non-governmental organizations) not currently or routinely engaged by existing programs. CDC will establish and expand partnerships with academic, healthcare, and other organizations to address common IPC failure modes; enhance correct implementation of IPC protocols and work processes; and strengthen healthcare worker training and competency assessment. This NOFO supports activities to assess and remove barriers to success, improve communication of IPC information and instructions to healthcare workers, and understand how to optimize the layout and functional flow of healthcare environments and processes. This NOFO will support organizations uniquely positioned and have the capacity to advance the design, delivery, and effectiveness of IPC training, education, and competency assessment to improve healthcare worker IPC practice and increase health department support of healthcare IPC and outbreak response.  The work conducted supports public health and healthcare practice by informing development of guidance and recommendations; translating guidance and recommendations into practices implementable in diverse healthcare settings; and improving how healthcare and public health personnel are trained and how competencies are assessed.  The recipients supported through this two-component NOFO will lead efforts to improve implementation of healthcare IPC. Strategies within Component 1, improving the safety and quality of healthcare and protecting healthcare personnel and patients by strengthening IPC, will improve healthcare facility structure, design, and organization; optimize materials and equipment design and safe use across healthcare settings; improve IPC work processes, procedures, and practices; promote standard practices to ensure healthcare environments are safe for healthcare personnel and patients, including by optimizing the safety of the air, water, or surfaces in the healthcare environment; and strengthen healthcare IPC preparedness.  Component two, strengthening healthcare personnel IPC training, education, and competency assessment, seeks to develop and evaluate innovative and effective IPC training and education approaches; and implement improved or novel approaches to healthcare personnel competency assessment. Component 2 also includes improving the ability of the U.S. public health workforce to support healthcare IPC and prevent and respond to healthcare-associated infections (HAI) and antibiotic resistance (AR).  In 2020, CDC launched Project Firstline, a collaborative of healthcare, public health, and academic partners committed to strengthening healthcare IPC practice and training. This NOFO supports Project Firstline implementation through strategies that improve the design and effectiveness of training and education for healthcare personnel.  By engaging a diverse set of partners and investing in work that supports a broad range of healthcare personnel populations and healthcare settings, this work supports CDC’s efforts to strengthen health equity, protect populations at increased risk for negative outcomes, and address disparities in IPC training and competencies.  Successful applicants will demonstrate specialized expertise, infrastructure, technological capabilities, and partners to strengthen healthcare IPC. Work proposed can be complementary to but must not be duplicative of work funded by CDC through any other mechanism. Types of organizations that may be funded through this cooperative agreement include, but are not limited to, private and state-controlled academic institutions, healthcare systems, clinicians and other healthcare professionals, non-governmental organizations, healthcare professional organizations, and other institutions with expertise that can improve healthcare IPC in the United States.
    Due Date: Anticipated 3/15/2022
    Funding Amount: TBD
    Website (search for RFA#):
  • Forecasted – RFA-IP-22-003: Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19: The purpose of this notice of funding opportunity (NOFO) is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.
    Due Date: Anticipated 11/01/2021
    Funding Amount: $4,000,000
    Website (search for RFA#):

National Science Foundation

National Science Foundation

wdt_ID Sponsor Program Funding Deadline
1 NSF RAPID: Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) $200,000 Check with program officers
2 NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) $200,000 (RAPID) & supplemental funding requests Check with program officers
5 NSF Ecology and Evolution of Infectious Diseases* $2,500,000 total 11/17/2021 & annually thereafter
7 NSF Research on Emerging Technologies for Teaching and Learning (RETTL) (20-612) $850,000 1/25/2021; 10/18/2021; 10/17/2022
11 NSF Dynamics of Integrated Socio-Environmental Systems (DISES) (20-579 ) DISES Research Projects: $1,600,000
DISES-RCN Awards: $500,000
11/21/2021 & annually thereafter
12 NSF Innovations in Graduate Education (IGE) Program (20-595) $1,000,000 3/25/2022; annually thereafter
13 NSF Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels) (NSF 20-105) Based on applicable program (NSF 21-509; PD 20-7909, NSF PD 20-1491) Rolling deadlines
15 NSF, NIH, and other agencies. Note: NIH mentions supporting "development of CPS research and technology to facilitate medical treatment during a national crisis (e.g., SARS-CoV-2)" (see Section II.D.3 of the program solicitation for details). Cyber-Physical Systems (CPS) $500,000 for 3 years
$500,001-$1,200,000 for 3 years
12/31/2021 for Small & Medium Proposals
17 NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) TBD No set deadline

Other Sponsors & Funding Opportunities

Other Sponsors

wdt_ID Sponsor Program Funding Deadline
1 Mozilla COVID-19 Solutions Fund $50,000 Applications accepted on a rolling basis
2 Department of Energy Invitation for COVID-19 scientific questions DOE Resources 3/18/2020 - Review starts 3/18 but applications accepted on a rolling basis
60 U.S. International Development Finance Corporation Global Health and Prosperity Initiative $5,000,000 to $500,000,000 No deadline; applications accepted on a rolling basis
62 Gates Foundation COVID-19 Therapeutics Accelerator Share ideas Ongoing
64 Biogen Foundation Biogen Foundation’s COVID-19 Response Unspecified (up to $10 million in total funding) Unspecified (accepting applications)
71 Allen Institute COVID-19 Open Research Dataset Challenge (CORD-19) Resource
73 Google Google Cloud Research Credits GCP Credits - worth up to $5,000 for faculty and $10,000 for PhD Candidates Ongoing
74 JEDI Group Joint European Disruptive Initiative (JEDI) – Billion Molecules Against COVID-19 JEDI Grand Challenge Stage 1: 250,000 Euros
Stage 2: 250,000 Euros
Stage 3: 1,000,000 Euros
Stage 1: 7/17/2020, with subsequent due dates after
78 Cystic Fibrosis Foundation Clinical Research Award (may involve COVID-19-relevant research) $150,000 per year for 3 years for single-center
$350,000 per year for 3 years for multi-center
Spring Cycle: 8/164/2021 for Letter of Intent; 1/25/2022 for full application
Fall Cycle: Coming soon

79 Cystic Fibrosis Foundation Clinical Pilot and Feasibility Award (may involve COVID-19-relevant research) $80,000 per year for up to 2 years Spring Cycle: 8/16/2021 for Letter of Intent; 1/25/2022 for full application
Fall Cycle: Coming soon

The Robert Wood Johnson Foundation

Robert Wood Johnson Foundation (RWJF)

wdt_ID Sponsor Program Funding Deadline
6 RWJF Evidence for Action: Investigator-Initiated Research to Build a Culture of Health Not specified Rolling
8 RWJF Evidence for Action: Innovative Research to Advance Racial Equity No defined amount. Rolling
9 RWJF Pioneering Ideas: Exploring the Future to Build a Culture of Health Average award is $315,000 4/30/2021 for Letter of Intent (optional); 6/09/2021 for full proposal

Internal UW-Madison Funding Opportunities

UWCCC BioBank – COVID 19-Related Blood Samples for Research

Internal UW-Madison Opportunities

wdt_ID Sponsor Program Funding Deadline
1 Wisconsin Partnership Program Wisconsin Partnership Progra, Varies by type of program See website for annual due dates
4 UWCCC Translational Science BioCore BioBank, UW SMPH & Wisconsin Partnership Program COVID-19 BioBank Initiative Request for Proposals Access to UWCCC BioBank resources (samples, clinical or survey data) to further COVID-19 research efforts Applications reviewed monthly, and approvals granted on a rolling basis
6 UW ICTR Novel Methods Award $50,000 Deadline has passed
7 UW ICTR Clinical & Community Outcomes Research $75,000 Deadline has passed
8 UW ICTR Collaborative Health Equity Research $50,000 Deadline has passed
9 UW ICTR Evidence to Implementation $52,500 Deadline has passed
10 UW ICTR Marshfield Clinic/Marshfield Clinic-UW Award $75,000 Deadline has passed
11 UW ICTR Stakeholder and Patient Engaged Research $100,000 Deadline has passed
12 UW ICTR Translational Basic & Clinical Research Pilot Awards $50,000 12/21/2020 for Letter of Intent; 2/22/2021 for Full Application
13 Wisconsin Alumni Research Foundation Fall Research Competition Average awards is about $60,000 September annually

Fast Grants Funding for COVID-19 Science

Note: Applications to Fast Grants is currently paused due to receipt of a very large number of qualified submissions. They may be reopened again in the future. Please go to the Fast Grants website to sign up if you’d like to be notified when they are reopened.
• Link is:

About Fast Grants:

Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, Fast Grants invites you to apply for a grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If approved, you’ll receive payment as quickly as the University can receive it. Below are brief instructions, followed by FAQs:

(A) Instructions:

(1) Fill out the application: The application form should take less than 30 minutes.

(B) Frequently Asked Questions (FAQs)

(1) Who is eligible to apply for a Fast Grant?
You must be:

  • A PI at an academic institution;
  • Already working on a project that could help with the COVID-19 pandemic within the next six months;
  • In need of additional funding to complete the project;
  • Researchers outside the US are eligible for funding.

(2) Why the six month constraint?
Most existing funding bodies focus on supporting longer-term work. Given COVID-19’s human costs, speed is of paramount importance.

(4) Who will make grant decisions?
A panel of biomedical scientists will make funding recommendations to Emergent Ventures.

(5) What can a Fast Grant be used for?
Fast Grants must be used solely to expedite COVID-19-related science. Beyond that, the grant recipient has complete discretion over how it is spent.

(6) What criteria will panelists use?
Fast Grants prefers projects that are cheap (so that funding dollars go further) and that will yield results quickly (during COVID-19, days matter).

(7) Does the grant go to the PI or to the university?
This is at the discretion of the applicant.

(8) When can I apply?
Fast Grants opened at 12:00 Pacific Time on Tuesday, April 7, 2020.  The first round of awards was announced starting on April 12.

(9) What conditions apply?

  • You must use the grant to work on COVID-19-related science.
  • You must send monthly updates, summarizing your progress, for 6 months (can be as simple as a single-paragraph email).
  • You must upload all manuscripts reporting work supported by the grant to a preprint server such as bioRxiv or arXiv upon submission to a peer-reviewed journal.
  • In line with Gates Foundation policy, will pay at most 10% in overhead costs to the university.

(10) How do IP rights work?
Apart from the open science publication requirement above, there are no IP restrictions associated with Fast Grants.

(11) Who administers Fast Grants?
Fast Grants is a part of Emergent Ventures, a project at the Mercatus Center at George Mason University. For Canadian recipients, Fast Grants makes funding recommendations to the Thistledown Foundation.

(12) Will the identities of grant recipients be made public?
This shall be at the recipient’s discretion. Fast Grants will list those who agree to be named and provide regular updates on the total dollars that have been allocated.